曲马多中毒患者出现显著且迁延的5-羟色胺毒性:一项药代动力学研究
本文报道一例21岁男性肾移植患者,自服曲马多750 mg、索他洛尔200 mg、普萘洛尔400 mg和劳拉西泮6 mg后出现短暂心血管衰竭和迁延的5-羟色胺毒性,需镇静、肌松和赛庚啶治疗。药代动力学研究显示曲马多和M1半衰期正常,但M2(26.5 h)和M5(16.7 h)半衰期延长,M2代谢比显著升高。基因分型显示CYP2D6正常代谢型,提示帕罗西汀和普萘洛尔抑制CYP2D6导致M2生成增加。仅M2在48小时内维持足够浓度可解释迁延的5-羟色胺毒性。
要点
- 曲马多中毒患者若合并使用帕罗西汀和普萘洛尔(CYP2D6强抑制剂),应警惕迁延的5-羟色胺毒性。
- 本病例中曲马多750 mg中毒后出现短暂心血管衰竭和迁延5-羟色胺毒性,需镇静、肌松和赛庚啶治疗。
- 药代动力学显示M2半衰期26.5 h、M5半衰期16.7 h延长,M2代谢比197(较正常升高1000倍)。
- 基因分型为CYP2D6正常代谢型,提示毒性由药物相互作用抑制CYP2D6所致,而非遗传多态性。
- M2在48小时内维持足够浓度可能是迁延5-羟色胺毒性的原因,监测和延长观察窗口很重要。
适用人群与场景
- 曲马多中毒患者,尤其是合并使用CYP2D6抑制剂(如帕罗西汀、普萘洛尔)或肝肾功能不全者;本病例为21岁男性肾移植患者,长期使用霉酚酸酯、他克莫司、泼尼松和帕罗西汀。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 出现迁延5-羟色胺毒性时,给予镇静、肌肉麻痹和赛庚啶治疗;本病例经上述处理结局良好。
红旗征与不能漏的情况
- 曲马多中毒后出现短暂心血管衰竭和迁延的5-羟色胺毒性,需警惕并积极处理。
研究设计与关键结果
- 个案报道(n=1):21岁男性自服曲马多750 mg、索他洛尔200 mg、普萘洛尔400 mg和劳拉西泮6 mg后出现短暂心血管衰竭和迁延5-羟色胺毒性;药代动力学显示曲马多半衰期6.1 h、M1半衰期7.1 h正常,M2半衰期26.5 h、M5半衰期16.7 h延长;M1代谢比0.12(降低2倍),M2代谢比197(升高1000倍),M5代谢比0.12(正常);基因分型为CYP2D6正常代谢型,提示帕罗西汀和普萘洛尔抑制CYP2D6
证据类型、等级与局限
- 证据类型:个案报道(病例报告)加药代动力学研究;局限:单病例、样本量小,结果需进一步验证。
对床旁实践的改变
- 对曲马多中毒患者,应询问是否合用帕罗西汀、普萘洛尔等CYP2D6抑制剂,并延长观察时间以发现迁延的5-羟色胺毒性;治疗上可能需要镇静、肌松和赛庚啶。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Tramadol poisoning rarely causes serotonin toxicity, which mechanisms remain poorly understood. We investigated alterations in tramadol pharmacokinetics in a tramadol-poisoned patient who presented with marked and prolonged serotonin toxicity.
CASE REPORT: A 21-year-old male self-ingested 750 mg-tramadol, 200 mg-sotalol, 400 mg-propranolol and 6 mg-lorazepam. He was a kidney transplant patient treated with mycophenolate, tacrolimus, prednisone, and paroxetine. He developed transitory cardiovascular failure and prolonged serotonin toxicity requiring sedation, muscle paralysis, and cyproheptadine, with a favorable outcome.
METHODS: We measured plasma concentrations of tramadol, M1, M2, and M5 using liquid-chromatography-tandem mass spectrometry, calculated elimination half-lives and metabolic ratios of the compounds, and genotyped cytochromes involved in tramadol metabolism.
RESULTS: Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged. M1 metabolic ratio (0.12) was 2-fold reduced, M2 metabolic ratio (197) 1000-fold increased and M5 metabolic ratio (0.12) normal. This metabolic profile in a patient with normal CYP2D6-metabolizer status based on genotyping supports CYP2D6 inhibition by paroxetine and propranolol, two strong mechanism-based inhibitors. Only M2 present in sufficient concentrations up to 48 h could explain the prolonged serotonin toxicity.
CONCLUSION: Marked and prolonged serotonin toxicity was attributed to increased M2 production due to paroxetine- and propranolol-related CYP2D6 inhibition of tramadol metabolism.
参考来源
- Bianconi G, Malissin I, Labat L, et al. Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. Clin Toxicol (Phila). 2021. PMID: 34287102. doi:10.1080/15563650.2021.1955912
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。